Elicio Therapeutics (ELTX) Operating Leases (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Operating Leases for 7 consecutive years, with $4.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 17.11% year-over-year to $4.6 million; the trailing twelve-month figure through Jun 2026 stood at $4.6 million (down 17.11% YoY), and the FY2025 full-year result was $4.1 million, down 19.8% from the prior year.
• Operating Leases declined to $4.6 million in Q2 2026 per ELTX's latest filing, from $4.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $7.4 million in Q2 2023 and bottomed at $297000.0 in Q1 2023.
• Historically, Operating Leases has averaged $5.2 million across 5 years, with a median of $5.5 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Operating Leases slumped 92.85% in 2023, then surged 2146.46% in 2024.
• Over 5 years, Operating Leases stood at $6.8 million in 2022, then fell by 11.52% to $6.0 million in 2023, then retreated by 15.02% to $5.1 million in 2024, then slipped by 19.8% to $4.1 million in 2025, then rose by 12.68% to $4.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $4.6 million, $4.9 million, and $4.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.